Literature DB >> 12779299

Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States.

Lydia A Bazzano1, Jiang He, Paul Muntner, Suma Vupputuri, Paul K Whelton.   

Abstract

BACKGROUND: Few studies have examined the relationship between cigarette smoking and novel risk factors for cardiovascular disease in a general population or have included a biochemical marker of current smoking.
OBJECTIVE: To examine the relationship between cigarette smoking and serum C-reactive protein, fibrinogen, and homocysteine levels.
DESIGN: Cross-sectional study.
SETTING: The U.S. general population. PATIENTS: 4187 current smokers, 4791 former smokers, and 8375 never-smokers 18 years of age or older who participated in the Third National Health and Nutrition Examination Survey conducted between 1988 and 1994. MEASUREMENTS: Serum C-reactive protein levels were categorized as detectable (2.2 to 9.9 mg/L) or clinically elevated (> or =10 mg/L), and fibrinogen and homocysteine levels were defined as elevated if in the 85th percentile or greater (11.1 micromol/L and 12.7 mmol/L, respectively).
RESULTS: After adjustment for traditional cardiovascular disease risk factors, cigarette smoking was related to elevated levels of C-reactive protein, fibrinogen, and homocysteine. Compared with never smoking cigarettes, self-reported current cigarette smoking was associated with a C-reactive protein level in the detectable (odds ratio, 1.66 [95% CI, 1.40 to 1.97]; P < 0.001) or clinically elevated (odds ratio, 1.98 [CI, 1.57 to 2.51]; P < 0.001) ranges, with elevated levels of fibrinogen (odds ratio, 2.15 [CI, 1.65 to 2.80]; P < 0.001) and homocysteine (odds ratio, 2.10 [CI, 1.62 to 2.74]; P < 0.001). There were positive and significant dose-response relationships between measures of cigarette smoking (cigarettes per day, pack-years, and serum cotinine levels) and elevated levels of novel risk factors.
CONCLUSIONS: These findings suggest that inflammation and hyperhomocysteinemia may be important mechanisms by which smoking promotes atherosclerotic disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12779299     DOI: 10.7326/0003-4819-138-11-200306030-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  109 in total

1.  Aspirin adherence, aspirin dosage, and C-reactive protein in the first 3 months after acute coronary syndrome.

Authors:  Ian M Kronish; Nina Rieckmann; Daichi Shimbo; Matthew Burg; Karina W Davidson
Journal:  Am J Cardiol       Date:  2010-10-15       Impact factor: 2.778

2.  Directionality of the relationship between depressive symptom dimensions and C-reactive protein in patients with acute coronary syndromes.

Authors:  Jonathan A Shaffer; Donald Edmondson; William F Chaplin; Joseph E Schwartz; Daichi Shimbo; Matthew M Burg; Nina Rieckmann; Karina W Davidson
Journal:  Psychosom Med       Date:  2011-06-02       Impact factor: 4.312

Review 3.  C-reactive protein and risk of cardiovascular disease: evidence and clinical application.

Authors:  Paul M Ridker; Shari S Bassuk; Peter P Toth
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

4.  Cigarette smoking is a risk factor for Alzheimer's Disease: an analysis controlling for tobacco industry affiliation.

Authors:  Janine K Cataldo; Judith J Prochaska; Stanton A Glantz
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

5.  Long lasting effects of smoking: breast cancer survivors' inflammatory responses to acute stress differ by smoking history.

Authors:  Jeanette M Bennett; Ronald Glaser; Rebecca R Andridge; Juan Peng; William B Malarkey; Janice K Kiecolt-Glaser
Journal:  Psychoneuroendocrinology       Date:  2012-06-21       Impact factor: 4.905

6.  Screening for coronary heart disease: cardiology through the oncology looking glass.

Authors:  D Douglas Miller; Leslee J Shaw
Journal:  J Nucl Cardiol       Date:  2005 Mar-Apr       Impact factor: 5.952

Review 7.  Biomarkers to assess the utility of potential reduced exposure tobacco products.

Authors:  Dorothy K Hatsukami; Neal L Benowitz; Stephen I Rennard; Cheryl Oncken; Stephen S Hecht
Journal:  Nicotine Tob Res       Date:  2006-08       Impact factor: 4.244

Review 8.  Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents.

Authors:  Jian Shen; Jose M Ordovas
Journal:  Clin Chem       Date:  2008-12-12       Impact factor: 8.327

9.  Effects of smoking in patients treated with cardiac resynchronization therapy.

Authors:  Laura Perrotta; Brunilda Xhaferi; Marco Chiostri; Paolo Pieragnoli; Giuseppe Ricciardi; Luigi Di Biase; Andrea Natale; Ilaria Ricceri; Mazda Biria; Dhanunjay Lakkireddy; Alessandro Valleggi; Michele Emdin; Federica Michelotti; Giosuè Mascioli; Angela Pandozi; Massimo Santini; Luigi Padeletti
Journal:  Intern Emerg Med       Date:  2012-12-19       Impact factor: 3.397

10.  Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.

Authors:  Eliseu Felippe dos Santos; Estela Natacha Brandt Busanello; Anelise Miglioranza; Angela Zanatta; Alethea Gatto Barchak; Carmen Regla Vargas; Jonas Saute; Charles Rosa; Maria Júlia Carrion; Daiane Camargo; André Dalbem; Jaderson Costa da Costa; Sandro René Pinto de Sousa Miguel; Carlos Roberto de Mello Rieder; Moacir Wajner
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.